Naaju Breaking News, Live Updates, Latest Headlines, Viral News, Top Stories, Trending Topics, Videos
[ad_1]
Despite the setback in negotiations with the national government for the supply of coronavirus vaccines, the laboratory Pfizer and his partner BioNTech announced the achievement of a new clinical trial in nine passes, including Argentina, to check the effectiveness of the drug in pregnant women.
“The phase 2 and 3 trial will recruit some 4000 healthy pregnant women in the United States, Canada, Argentina, Brazil, Chile, Mozambique, South Africa, the United Kingdom and Spain ”, indicates the press text quoted by the Tlam news agency.
In addition, the study will further assess the safety, tolerability and immunogenicity of the Pfizer / BioNTech Covid-19 vaccine (BNT162b2) for prevent disease in healthy pregnant women 18 years and older, according to the press release.
Meanwhile, William Gruber, senior vice president of clinical inoculation research and development at Pfizer, explained that “pregnant women have an increased risk of complications and of developing severe coronavirusIt is therefore essential that we develop a safe and effective vaccine for this population. “
The Phase 2 and 3 trial is designed as a randomized, placebo-controlled study that will reach approximately 4,000 healthy pregnant women over 18 years of age. who will be vaccinated between weeks 24 and 34 of gestation.
.
[ad_2]
Source link
